Search

David J Unett

from San Diego, CA
Age ~57
Get Report
Also known as:
David John Unett, Dave Unett
Phone and address:
11422 Cypress Terrace Pl, San Diego, CA 92131
(858) 693-7459
Related to:
Graham A Luecke, 37Merrie Anne Kennebeck, 54Velma K Hubbard, 93Gerald A Hubbard, 91Victoria WilsonDonna R Unett, 60Rita WilsonSteve C Wilson, 61
Connected to:
Mark D Unferth, 57Kerry A Unflat, 47Kristina L Unfred, 60Thresa R Unfreid, 61Chip A Unfried, 55Daniel W Unfried, 77Alain Ung, 58Alice A Ung, 84Amy C Ung, 53Aydmara Ung, 54

David Unett Phones & Addresses

  • 11422 Cypress Terrace Pl, San Diego, CA 92131 (858) 693-7459
  • 404 Encinitas Blvd, Encinitas, CA 92024 (760) 943-7933
  • 4149 Durbin Dr, The Colony, TX 75056
  • Dallas, TX
  • Lewisville, TX
  • Mira Loma, CA

Work

Company: Beacon discovery Sep 2016 Position: Co-founder and vice president, receptor pharmacology

Education

School / High School: Ut Southwestern Medical Center 1996 to 2000 Specialities: Pharmacology

Skills

Gpcrs • Lead Optimization • Drug Discovery • Drug Design • Receptor Pharmacology • High Throughput Screening • Cellular Assays • Project Management • Pharmacology • Assay Development • Lead Change • Drug Development • Life Sciences • Biotechnology • Ind • Biopharmaceuticals • Clinical Development • Molecular Biology • Technology Transfer • Biochemistry • Toxicology • Organic Chemistry • Pharmaceutical Industry • Biomarkers

Emails

d***[email protected]

Industries

Pharmaceuticals

Resumes

Resumes

David Unett Photo 1

Co-Founder And Vice President, Receptor Pharmacology

View page
Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Beacon Discovery
Co-Founder and Vice President, Receptor Pharmacology
Arena Pharmaceuticals Jul 2012 - Aug 2016
Vice President, Receptor Pharmacology
Arena Pharmaceuticals Mar 2005 - Jul 2012
Senior Director, Receptor Pharmacology and Screening
Arena Pharmaceuticals Mar 2001 - Mar 2005
Scientist, Associate Director and Director
Bunsen Rush Laboratories Jan 2000 - Mar 2001
Principal Scientist
Education:
Ut Southwestern Medical Center 1996 - 2000
The University of Texas at Dallas 1992 - 1996
The University of Manchester 1989 - 1992
Doctorates, Doctor of Philosophy, Chemistry
Skills:
Gpcrs
Lead Optimization
Drug Discovery
Drug Design
Receptor Pharmacology
High Throughput Screening
Cellular Assays
Project Management
Pharmacology
Assay Development
Lead Change
Drug Development
Life Sciences
Biotechnology
Ind
Biopharmaceuticals
Clinical Development
Molecular Biology
Technology Transfer
Biochemistry
Toxicology
Organic Chemistry
Pharmaceutical Industry
Biomarkers

Publications

Us Patents

Human G Protein-Coupled Receptor And Modulators Thereof For The Treatment Of Cell Death-Related Disorders

View page
US Patent:
7776558, Aug 17, 2010
Filed:
Mar 15, 2004
Appl. No.:
10/549228
Inventors:
Sonia Villegas - San Diego CA, US
Gregory S. Kelner - San Diego CA, US
David J. Unett - San Diego CA, US
Joel Gatlin - San Diego CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
G01N 33/567
C07K 14/705
US Classification:
435 721, 435 71, 435 72, 436501
Abstract:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells. In certain embodiments, the GPCR is neuroprotective or myoprotective. In certain embodiments, the GPCR is a Humanin receptor. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of neurodegenerative diseases in general, including Alzheimer's disease, Parkinson's disease, prion-associated disease, stroke and motor-neuron disease in particular, peripheral neuropathy, cerebral amyloid beta-protein angiopathy, and ischemic heart disease, including myocardial infarction and congestive heart failure.

Human G Protein-Coupled Receptors For Metabolic-Related Disorders

View page
US Patent:
7829298, Nov 9, 2010
Filed:
Aug 31, 2004
Appl. No.:
10/930662
Inventors:
David J. Unett - San Diego CA, US
Ruoping Chen - San Diego CA, US
Jeremy G. Richman - San Diego CA, US
Daniel T. Connolly - Solana Beach CA, US
Huong T. Dang - San Diego CA, US
Bryan J. Choi - Bonita CA, US
James N. Leonard - San Diego CA, US
Yaron Hakak - San Diego CA, US
Chen W. Liaw - San Diego CA, US
Dominic P. Behan - San Diego CA, US
Derek T. Chalmers - Cardiff CA, US
Michael R. Lerner - Rancho Santa Fe CA, US
Kevin P. Lowitz - Sunnyvale CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
G01N 33/53
US Classification:
435 72
Abstract:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

3-Phenyl-Pyrazole Derivatives As Modulators Of The 5-Htserotonin Receptor Useful For The Treatment Of Disorders Related Thereto

View page
US Patent:
7884101, Feb 8, 2011
Filed:
Nov 20, 2006
Appl. No.:
11/602164
Inventors:
Bradley Teegarden - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Honnappa Jayakumar - San Diego CA, US
Peter I. Dosa - San Diego CA, US
Konrad Feichtinger - San Diego CA, US
Martin Casper - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert M. Jones - San Diego CA, US
David J. Unett - San Diego CA, US
Jin Sun Karoline Choi - San Diego CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/5355
C07D 413/10
US Classification:
5142365, 544111
Abstract:
The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor and are useful, optionally in combination with other pharmaceutical agents administered separately or together, in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.

Human G Protein-Coupled Receptors And Modulators Thereof For The Treatment Of Metabolic-Related Disorders

View page
US Patent:
20040142377, Jul 22, 2004
Filed:
Dec 6, 2002
Appl. No.:
10/314048
Inventors:
David Unett - San Diego CA, US
Ruoping Chen - San Diego CA, US
Jeremy Richman - San Diego CA, US
Daniel Connolly - Carlsbad CA, US
Huong Dang - San Diego CA, US
Bryan Choi - Bonita CA, US
James Leonard - San Diego CA, US
Yaron Hakak - San Diego CA, US
Chen Liaw - San Diego CA, US
Dominic Behan - San Diego CA, US
Derek Chalmers - Cardiff CA, US
Michael Lerner - Rancho Santa Fe CA, US
Kevin Lowitz - Somerset NJ, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
G01N033/53
A61K031/4439
US Classification:
435/007100, 514/341000
Abstract:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

Human G Protein-Coupled Receptors And Modulators Thereof For The Treatment Of Metabolic-Related Disorders

View page
US Patent:
20050004178, Jan 6, 2005
Filed:
Jul 23, 2004
Appl. No.:
10/897815
Inventors:
David Unett - San Diego CA, US
Ruoping Chen - San Diego CA, US
Jeremy Richman - San Diego CA, US
Daniel Connolly - Carlsbad CA, US
Chen Liaw - San Diego CA, US
Dominic Behan - San Diego CA, US
Derek Chalmers - Cardiff CA, US
Michael Lerner - Rancho Santa Fe CA, US
Huong Dang - San Diego CA, US
Bryan Choi - Bonita CA, US
James Leonard - San Diego CA, US
Yaron Hakak - San Diego CA, US
Kevin Lowitz - Sunnyvale CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K031/4439
G01N033/53
US Classification:
514341000, 435007100
Abstract:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

Human G Protein-Coupled Receptors And Modulators Thereof For The Treatment Of Metabolic-Related Disorders

View page
US Patent:
20070079392, Apr 5, 2007
Filed:
Nov 22, 2006
Appl. No.:
11/603625
Inventors:
Chen Liaw - San Diego CA, US
Dominic Behan - San Diego CA, US
Derek Chalmers - Cardiff CA, US
Michael Lerner - Rancho Santa Fe CA, US
Huong Dang - San Diego CA, US
Bryan Choi - Bonita CA, US
James Leonard - San Diego CA, US
Yaron Hakak - San Diego CA, US
Kevin Lowitz - Sunnyvale CA, US
David Unett - San Diego CA, US
Ruoping Chen - San Diego CA, US
Jeremy Richman - San Diego CA, US
Daniel Connolly - Carlsbad CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
A01K 67/027
G01N 33/53
C12P 21/06
C07D 403/02
C07K 14/705
US Classification:
800014000, 435007100, 800018000, 435069100, 435320100, 435325000, 546268100, 514341000
Abstract:
The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

3-Phenyl-Pyrazole Derivatives As Modulators Of The 5-Ht2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto

View page
US Patent:
20070244086, Oct 18, 2007
Filed:
Nov 17, 2005
Appl. No.:
11/597306
Inventors:
Bradley Teegarden - San Diego CA, US
Yifeng Xiong - San Diego CA, US
Honnappa Jayakumar - San Diego CA, US
Peter Dosa - San Diego CA, US
Konrad Feichtinger - San Diego CA, US
Martin Casper - San Diego CA, US
Juerg Lehmann - San Diego CA, US
Robert Jones - San Diego CA, US
David Unett - San Diego CA, US
Jin Karoline Choi - San Diego CA, US
International Classification:
A61K 31/4155
A61K 31/397
A61K 31/4178
A61K 31/454
A61K 31/496
A61K 31/5355
A61K 31/541
A61K 31/553
A61P 29/00
C07D 231/12
C07D 231/16
C07D 401/12
C07D 403/12
C07D 405/12
C07D 409/12
C07D 413/12
C07D 417/12
C07D 487/08
US Classification:
514210200, 514211150, 514227800, 514236500, 514254040, 514326000, 514385000, 514406000, 540544000, 544140000, 544371000, 544060000, 546211000, 548314700, 548356100, 548364100, 548518000, 548952000
Abstract:
The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HTserotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HTserotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

Methods For Producing Olfactory Gpcrs

View page
US Patent:
20080009015, Jan 10, 2008
Filed:
Nov 15, 2004
Appl. No.:
10/579399
Inventors:
Gene Hung - San Diego CA, US
Daniel Ortuno - Vista CA, US
David Unett - San Diego CA, US
Joel Gatlin - San Diego CA, US
Assignee:
Arena Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07K 14/705
G01N 33/53
C12P 21/06
US Classification:
435007100, 435368000, 435069100, 530350000
Abstract:
The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications.
Control profile
David J Unett from San Diego, CA, age ~57 Get Report